<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548729</url>
  </required_header>
  <id_info>
    <org_study_id>4790</org_study_id>
    <nct_id>NCT01548729</nct_id>
  </id_info>
  <brief_title>Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis</brief_title>
  <acronym>PIM</acronym>
  <official_title>Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis : a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with end-stage cystic fibrosis (CF) and severe CF-related diabetes (CFRD) may&#xD;
      benefit from combined lung-pancreatic islet transplantation. A recent case series showed that&#xD;
      combined bilateral lung and pancreatic islet transplantation is a viable therapeutic option&#xD;
      for patients with end-stage CF and CFRD. The use of different organs from a single donor may&#xD;
      lead to reduced immunogenicity. As the prevalence of CFRD has increased dramatically with the&#xD;
      improved life expectancy of patients with CF, islet transplantation should be considered at&#xD;
      the end-stage CF. By restoring metabolic control, the investigators hypothesize that islet&#xD;
      transplantation may improve the management of CF patients undergoing lung transplant and&#xD;
      decrease the complication rate in the early postoperative period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2012</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic efficiency at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Combined criteria based on the 4 following criteria: weight increase &gt; 5% compared to inclusion, fasting blood glucose &lt; 1.1 g/l at 12 months post-transplant (beta score criterion), Reducing insulin requirements (expressed in UI/day) compared to inclusion &amp; decreased in HbA1c &gt;= 0.5% (in absolute value) compared to inclusion Success is defined by achieving at least three of these criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio [C-peptide stimulated T6min/ C-peptide basal T0]</measure>
    <time_frame>1 year after transplant</time_frame>
    <description>Δ C peptide = [ C-peptide stimulated T6min/ C-peptide basal T0] Success if Δ C peptide &gt; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio [C-peptide/Glucose-Creatinine] &amp; ratio [C-peptide/Glucose]</measure>
    <time_frame>Every week during the first month, and every month during 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Every 3 months during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide stimulated by glucagon</measure>
    <time_frame>Every 3 months during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio [C-peptide stimulated T6min/ C-peptide basal T0]</measure>
    <time_frame>Every 3 months during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microalbuminuria &amp; proteinuria</measure>
    <time_frame>Every 3 months during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin requirements</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
    <description>Unit/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of minor hypoglycemia</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
    <description>defined by a blood glucose level &lt; 0.6g/L at which the patient is capable of self-sugaring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of major hypoglycemia</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability (MAGE)</measure>
    <time_frame>Every 6 months during 1 year after transplant</time_frame>
    <description>by continuous glycemic measurement Holter (CGMS) &amp; glycemic reader memory analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hypoglycemia</measure>
    <time_frame>Every 6 months during 1 year after transplant</time_frame>
    <description>by continuous glycemic measurement Holter (CGMS) &amp; glycemic reader memory analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume (FEV1)</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tiffeneau-Pinelli index</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
    <description>FEV1/FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature of pulmonary infection episodes and nature of acute lung rejection if need be</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score according to the mMRC scale</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation SaO2 room air</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median maximum expiration flow</measure>
    <time_frame>Every month during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of pulmonary rejection</measure>
    <time_frame>Every visit during 1 year after transplant</time_frame>
    <description>requiring a corticosteroid bolus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of post-transplant hospitalization and during the follow-up</measure>
    <time_frame>Every visit during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Every visit during 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Every visit during 1 year after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Diabetes Related Cystic Fibrosis</condition>
  <condition>Insulin-dependent Diabetes</condition>
  <arm_group>
    <arm_group_label>Patient with cystic fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with end-stage cystic fibrosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combined pancreatic islet and lung transplantation</intervention_name>
    <description>Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis</description>
    <arm_group_label>Patient with cystic fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient with cystic fibrosis&#xD;
&#xD;
          -  Patient able to respect the protocol procedures&#xD;
&#xD;
          -  Patient with end-stage respiratory insufficiency indicating a lung transplant&#xD;
&#xD;
          -  Clinical history of cystic fibrosis related diabetes and/or insulin-dependent&#xD;
             diabetes, with no residual insulin secretion (C-peptide &lt; 0,5 ng/mL) and/or no&#xD;
             response to IV glucagon stimulation: [peak stimulated C-peptide (T6min)/basal plasma&#xD;
             C-peptide(T0)] &lt; 2. The absence of insulin secretion will be verified 2 times before&#xD;
             inclusion&#xD;
&#xD;
          -  Evolution of diabetes for over 3 years&#xD;
&#xD;
          -  Patient whose glycaemic control obtained with insulin therapy is not satisfactory and&#xD;
             could significantly alter quality of life (HbA1c &gt; 7% and/or MAGE index &gt; 1,25). This&#xD;
             situation is assessed by a diabetologist.&#xD;
&#xD;
          -  Social Security membership or benefit from Social Welfare&#xD;
&#xD;
          -  Patient who received the results of the medical evaluation required&#xD;
&#xD;
        Non-inclusion criteria:&#xD;
&#xD;
          -  Patient with contra-indication for undergo a lung transplant&#xD;
&#xD;
          -  Patient with an indication of heart, liver or kidney transplantation&#xD;
&#xD;
          -  Patient for which poor therapeutic compliance is expected&#xD;
&#xD;
          -  Patient under oral antidiabetic drug&#xD;
&#xD;
          -  In women of childbearing potential: pregnancy test (urine and / or blood) positive,&#xD;
             lactation, or unwilling to use effective contraception for the duration of the study&#xD;
             until 3 months after the end . Men: procreation project during the study period up to&#xD;
             3 months after its end, or unwilling to use effective contraception patient.&#xD;
&#xD;
          -  Active infection, including hepatitis B, hepatitis C, HIV&#xD;
&#xD;
          -  Any history of malignancy within the past 5 years, with the exception of cutaneous&#xD;
             basal cell carcinomas completely resected. The history of breast or melanoma cancers&#xD;
             are an absolute contraindication&#xD;
&#xD;
          -  Alcoholic intoxication or drug addiction&#xD;
&#xD;
          -  Anemia (hemoglobin Hb &lt;10g / dL in women and Hb &lt;11 g / dL in men), lymphopenia (&lt;1000&#xD;
             / uL), neutropenia (&lt;1500 / uL) or thrombocytopenia (&lt;100,000 / uL).&#xD;
&#xD;
          -  Persistent elevated liver enzymes at baseline&#xD;
&#xD;
          -  Portal hypertension identified by oesophageal varice and/or hypersplenism (platelets &lt;&#xD;
             120 000 /mm3) or Child-Pugh score &gt; 6.&#xD;
&#xD;
          -  Use of a medical treatment under investigation within 4 weeks before inclusion&#xD;
&#xD;
          -  All medical situation assessed by an investigator which could interfere with the good&#xD;
             management of the project&#xD;
&#xD;
          -  Patient restricted of freedom or unable to give his consent&#xD;
&#xD;
          -  Patient has been included in another study that could interfere with the results of&#xD;
             the study&#xD;
&#xD;
          -  Contraindications to the use of experimental drugs (Cellcept®, prednisone, Prograf,&#xD;
             prednisolone, methylprednisolone, and pancreatic islets)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence KESSLER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Yves BENHAMOU, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Grenet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL FOCH DE SURESNES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles THIVOLET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry BERNEY, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE ROMAND DE TRANSPLANTATION - SUISSE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRCM AdulteCHU de Grenoble, Hôpital A. Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38 043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologie, CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Réanimation Cardiovasculaire et Thoracique, Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Cardiaque, CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Radiologie Interventionnelle, CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie, Hôpital A. MICHALLON , CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie et chirurgie de la Transplantation, Groupement Hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69 437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de médecine de la transplantation et immunologie clinique, Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRCM adulte, Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Pavillon médical</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'imagerie radiologique et de médecine nucléaire, Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Thoracique, HOPITAL LOUIS PRADEL</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie, Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de la Clinique d'Endocrinologie, maladies métaboliques et Nutrition</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie et Immuno-transplantation</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Radiologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'endocrinologie, diabète et maladies métaboliques</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Anesthésie-Réanimations chirurgicales, Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Anesthésie-Réanimations Chirurgicales</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de chirurgie, Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie, Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Radiologie, Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité d'Endocrinologie, Diabétologie et Médecine Métabolique - Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Imagerie - Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Thoracique et Transplantation Pulmonaire - Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Diabetes Related Cystic Fibrosis</keyword>
  <keyword>Lung transplantation</keyword>
  <keyword>Pancreatic islets</keyword>
  <keyword>Insulin-dependent diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

